The key experts, we learn, consisted of a troika of psychiatrists: Dr. Allen Frances, Chairman of the Dept. of Psychiatry, Duke University; Dr. John P. Docherty, Professor and Vice Chairman of Psychiatry, Cornell University; and David A Kahn, Associate Clinical Professor of Psychiatry, Columbia University.
These men accepted a total of $942,669, mostly in the form of “unrestricted educational grants” through their newly formed company, Expert Knowledge Systems (EKS), to prepare practice guidelines for the treatment of schizophrenia. The guidelines, which formed the basis for the Texas Medication Algorithm Project (TMAP, pronounced T-Map), endorsed the use of Risperdal as a first line treatment, dislodging the first generation of antipsychotic medicines (FGAs) from that position.
Friday, January 13, 2012
The Risperdal trial in Texas, cont’d: Establishing not just facts, but the yardstick by which facts are to be measured, and other matters | Somatosphere
via somatosphere.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment